In a recent InvestorIntel interview, Tracy Weslosky speaks with Dr. Rahul Kushwah, Co-Founder and COO of Predictmedix Inc. (CSE: PMED | OTCQB: PMEDF) about Predictmedix’s artificial intelligence powered infectious disease symptom screening solution for workplace health and safety.

In this InvestorIntel interview, which may also be viewed on YouTube (click here to subscribe to the InvestorIntel Channel), Dr. Kushwah went on to say, “You can open facilities and workplaces but it is about bringing in technologies that can create safety bubbles in those places. That is where our infectious disease symptom screening solution or Safe Entry Station comes into play. The technology can identify a host of symptoms associated with COVID-19.”

Speaking on the competitive advantages of Predictmedix’s Safe Entry Station Dr. Kushwah said, “It looks at several symptoms associated with infectious diseases. So, it is not just another fever scanner. At the same time, there is a deep learning algorithm that runs in the background. As more and more people pass through the system the system keeps on getting smarter.”

To watch the full interview, click here

About Predictmedix Inc.

Predictmedix Inc. is an artificial intelligence (“AI”) company developing disruptive tools for impairment testing and healthcare. It is intended that the Company’s cannabis and alcohol impairment detection tools will be used across various workplaces and by law enforcement agents. Its technology uses facial and voice recognition to identify both cannabis and alcohol impairment by utilizing multiple features along with numerous different data points. Testing does not require any body fluids or human intervention, thereby helping to remove human error and the potential for discrimination and prejudice.

The Company is also developing AI based screening for the healthcare industry. The recent advent of COVID-19 pandemic has placed unprecedented stress on the global economy and highlights the need for tools to help screen mass populations for infectious diseases, with the hope of preventing pandemics in the future. In turn, Predictmedix Inc. is expanding its proprietary AI technology to screen for infectious disease symptoms.

Additionally, psychiatric disorders such as depression, dementia and Alzheimer’s disease can carry a significant burden and early identification is the key to better management. To help address this, the Company is also expanding its proprietary AI technology to screen for psychiatric and/or brain disorders such as depression, dementia and Alzheimer’s disease.

To learn more about Predictmedix Inc., click here

Disclaimer: Predictmedix Inc. is an advertorial member of InvestorIntel Corp.

In a recent InvestorIntel interview, Tracy Weslosky speaks with Dr. Rahul Kushwah, Co-Founder and COO of Predictmedix Inc. (CSE: PMED | OTCQB: PMEDF) about ramping up their sales and business development efforts and provides an update on partnerships already in play.

Predictmedix is dedicated to health and wellness using artificial intelligence powered technologies. In this InvestorIntel interview, which may also be viewed on YouTube (click here to subscribe to the InvestorIntel Channel), Dr. Kushwah went on to provide an update on the Safe Entry Stations powered by Predictmedix’s proprietary infectious disease symptom screening technology. “We have had successful deployment with several companies including Fortune 500 companies such as Indian Oil,” Dr. Kushwah said.

Predictmedix has been actively signing partnerships with some of the major healthcare providers. “We have partnered with Max Healthcare which is one of the largest groups of hospitals in Asia…At the same time we have just deployed our technology at MGM Hospital in Mumbai and that is one of the largest COVID-19 clinics in India.”

To watch the full interview, click here

About Predictmedix Inc.

Predictmedix Inc. is an artificial intelligence (“AI”) company developing disruptive tools for impairment testing and healthcare. It is intended that the Company’s cannabis and alcohol impairment detection tools will be used across various workplaces and by law enforcement agents. Its technology uses facial and voice recognition to identify both cannabis and alcohol impairment by utilizing multiple features along with numerous different data points. Testing does not require any body fluids or human intervention, thereby helping to remove human error and the potential for discrimination and prejudice.

The Company is also developing AI based screening for the healthcare industry. The recent advent of COVID-19 pandemic has placed unprecedented stress on the global economy and highlights the need for tools to help screen mass populations for infectious diseases, with the hope of preventing pandemics in the future. In turn, Predictmedix Inc. is expanding its proprietary AI technology to screen for infectious disease symptoms.

Additionally, psychiatric disorders such as depression, dementia and Alzheimer’s disease can carry a significant burden and early identification is the key to better management. To help address this, the Company is also expanding its proprietary AI technology to screen for psychiatric and/or brain disorders such as depression, dementia and Alzheimer’s disease.

To learn more about Predictmedix Inc., click here

Disclaimer: Predictmedix Inc. is an advertorial member of InvestorIntel Corp.

As the world shifts to a “new” normal, employee and customer screenings will be commonplace and Predictmedix Inc. (CSE: PMED | OTCQB: PMEDF) and its solutions are leading the way.

The recent announcement by Predictmedix, regarding the partnership with McGill University, is another example of the relationships that Dr. Rahul Kushwah, COO of Predictmedix, is developing with major corporations and leading healthcare providers as it rolls out Artificial Intelligence (“AI”) health tech solutions.

Predictmedix aims to improve the healthcare system through innovative and cutting-edge digital health technologies. Currently, Predictmedix AI solutions focus on infectious-disease screenings, impairment detection, and remote patient monitoring.

The Company’s products use facial, thermal, video, and audio recognition technologies to determine when individuals are impaired, suffering from an infectious disease, or mental illness. One solution focuses on mass and rapid AI-based screening for COVID-19 symptoms.

Partnerships, Pilots, Trials and Installs – Where Does Predictmedix Find the Time

Earlier this month, Predictmedix announced partnering with a research group led by Dr. Samira Rahimi from McGill University’s Department of Family Medicine.

Dr. Rahimi’s research group will be working with Predictmedix and its three industry verticals:  (1) screening for infectious disease associated symptoms; (2) screening for alcohol or cannabis impairment; and, (3) mental health screening.

Dr. Rahul Kushwah commented, “We are extremely excited with the partnership with Dr. Samira Rahimi’s team. Dr. Rahimi is one of the most recognized AI – healthcare scientists in Canada and we look forward to with her and her research team for our 3 major verticals.”

The announcement with McGill is just the latest in a series of pilot projects, partnerships, and product rollouts that Predictmedix has successfully executed this year. Predictmedix believes that it is well-positioned for growth and to capture the current sales momentum into Q1/2021.

Recently, the Company announced that it will be deploying its COVID-19 screening technology along with alcohol and impairment screening technology at Indian Oil Corporation Ltd (NSE:IOC.NS), a multi-billion dollar India-based oil company, and the deployment of its mass screening technology for COVID-19 with Max Healthcare, one of the largest healthcare groups in South Asia, encompassing 14 hospitals with over 3000 doctors.

Predictmedix also announced a collaboration with India-tech giant Tech Mahindra Ltd (NSE: TECHM), to incorporate Predictmedix’s impairment detection technology and COVID-19 solutions into Tech Mahindra’s suite of technologies offered for workplace health and safety across the globe.

Closer to home, the Company, in conjunction with its partner Juiceworks Exhibits, successfully deployed its infectious disease screening technology at Flow Water in Aurora, Ontario, and a 24-hour pharmacy in Montreal, Quebec.

Used by employees on a daily basis, Predictmedix’s gateway screens individuals, in a non-invasive way, as they walk through and it triggers an alarm if symptoms associated with an infectious disease are detected, such as COVID-19, or signs of impairment due to alcohol or cannabis use.

The screening product consists of hardware, software, multi-spectral cameras, and specialized sensors that are assembled into a gateway, much like a metal detector in an airport, and communicates with Predictmedix’s AI model in the cloud.

Remote Patient Monitoring & Telehealth Enterprise Platform with Mobile Wellbeing Acquisition

In June, Predictmedix acquired Mobile Wellbeing, a remote patient monitoring platform, which is strategic for the Company in creating an enterprise platform and allows Predictmedix to enter the telehealth and clinical trials markets.

According to a recent by study Adroit Market Research, the Remote Patient Monitoring Market is anticipated to reach US$1.9 billion by 2026, growing at a CAGR of almost 13% from 2020 to 2026.

With current stay-at-home orders due to the COVID-19 health crisis, clinical drug trials shifted to remote monitoring from on-site monitoring. The U.S. Food and Drug Administration (“FDA”) now supports remote monitoring for oversight of clinical sites.

In addition, the Mobile Wellbeing platform is equally suited for use in long-term care facilities to care for elderly patients. Big Data features include assisted monitoring that allows for data collection, transmission, evaluation, and notification. Utilizing the latest off-the-shelf wearables, the platform has shown benefits such as improved patient health and also lowered the cost of care through remote monitoring.

Predictmedix anticipates the commercial launch of its remote patient monitoring platform Q1/2021 with some key, large-scale deployments in North America and Asia.

Predictmedix is currently trading at $0.46 with a market cap of $46.5M but with billion-dollar partners and a pipeline of projects in Q1/2021, clearly ready for a re-rating.

In a recent InvestorIntel interview, Tracy Weslosky speaks with Dr. Rahul Kushwah, Co-Founder and COO of Predictmedix Inc. (CSE: PMED | OTCQB: PMEDF), about their infectious disease screening technology and remote patient monitoring platform, Mobile Wellbeing.

In this InvestorIntel interview, which may also be viewed on YouTube (click here to subscribe to the InvestorIntel Channel), Dr. Kushwah talked about the successful North American deployment of Predictmedix’s infectious disease screening technology at Flow Water in Aurora, Ontario. Dr. Kushwah went on to provide an update on their Mobile Wellbeing platform. “It is in telehealth and telemedicine business, but it does more than that.” He continued, “It does something which is referred to as remote patient monitoring.” Dr. Kushwah added that Predictmedix is targeting clinical trials and long-term care markets with its Mobile Wellbeing platform. FDA now has very strong guidance which is promoting remote patient monitoring and that brings Predictmedix’s technology to the forefront.

In the interview Dr. Kushwah also said that Accenture, a multinational professional services company and a Fortune Global 500 company, recently wrote about how Predictmedix is innovating to help with the current COVID-19 pandemic (click here to read the article). “It should indicate to shareholders that not only our technology is disruptive but we are clearly in a market segment which is not only ballooning right now but is going to be huge as time goes by.” Dr. Kushwah commented. To watch the full interview, click here

About Predictmedix

Predictmedix develops AI technologies focused on areas which include screening for impairment, infectious disease and mental health, and a remote patient monitoring/telehealth platform, all of which play a vital role in health and safety. Their technologies are timely to assist with the current pandemic, as well as having lasting utility that goes beyond the current crisis, extending into workplace health, safety and compliance.

To learn more about Predictmedix Inc., click here

Disclaimer: Predictmedix Inc. is an advertorial member of InvestorIntel Corp.

Using artificial intelligence to mass screen for COVID-19

“It’s about the different verticals that we are addressing with Predictmedix,” says Dr. Rahul Kushwah, Co-Founder and COO of Predictmedix Inc. (CSE: PMED | OTCQB: PMEDF). “We are an artificial intelligence company and we are solving real-world problems.”

In an interview with InvestorIntel’s Tracy Weslosky, Dr.  Kushwah explains three of their vertical markets: “COVID-19 pandemic, we are all in the midst of it and we have a technology which is to mass screen for COVID-19. Similarly, impairment is a big issue when it comes to workplace and law enforcement and we have a solution for that. And the third vertical is mental illnesses. $300 billion spent in the US last year and there is so much subjectivity that goes into diagnosis and we are developing a solution to diagnose mental illnesses.”

“We have developed modules which look like metal detectors,” Dr.  Kushwah continued. “You walk through these modules and on the other end you have a green or red light. If someone is identified to be positive for COVID-19 symptoms a red light goes off – if not then you get a green light.” He continued, “it is a tool that you can use for mass screening in airports, transit hubs, malls, office building, government buildings, or anywhere you can imagine where you have big flow of people.” Dr. Kushwah also discusses the pitfalls of current telehealth and telemedicine platforms, and Predictmedix’s innovative solutions.

To access the complete interview, click here

Disclaimer: Predictmedix Inc. is an advertorial member of InvestorIntel Corp.

“We have developed a technology to screening for COVID-19 and the key is, it is a mass screening technology. The technology works with multispectral imaging and our AI algorithms, which are patent pending and sit on a cloud, and they communicate directly with the multispectral cameras. These cameras can be installed and as people are passing by, the technology will just screen them for COVID-19.” States Dr. Rahul Kushwah, Co-Founder and COO of Predictmedix Inc. (CSE: PMED | OTCQB: PMEDF), in an interview with InvestorIntel’s Tracy Weslosky.

Dr. Kushwah went on to say that the technology can be deployed in places where there is movement of large number of people like airports, shopping centers, malls, arenas, transit hubs, etc. He added, “If you want to control the next wave you have to ensure that there is no transmission of infection and the only way you can do that is by containment and to contain you have to identify.”

Dr. Kushwah also provided an update on the appointment of Microsoft Director of Business Development for AI solutions, Kapil Raval, as the Chairman of the Advisory Board. He said that Predictmedix is working very closely with the Indian Institute of Technology to scale up its technologies. Dr. Kushwah also said that Predictmedix has deployed its mass screening technology for COVID-19 with Max Healthcare. He continued, “Max Healthcare is one the largest healthcare group in South Asia…They have 14 hospitals with over 3000 doctors, and we have deployed our technology at their facilities. That is a phenomenal validation to what we have developed.”

To access the complete interview, click here

Disclaimer: Predictmedix Inc. is an advertorial member of InvestorIntel Corp.

“Even now there is nothing out there. Any tools that are in development are designed to measure THC. Just because you can measure THC does not mean you are looking at impairment. That is a big pandora’s box that no one is addressing. We are the first one in the space that is tackling impairment.” States Dr. Rahul Kushwah, Co-Founder and COO of Cultivar Holdings Inc. (CSE: CULT), in an interview with InvestorIntel’s Peter Clausi.

Dr. Kushwah went on to say that Cultivar is a cannabis technology company that has developed an artificial intelligence based impairment detection technology for the workplace and law enforcement and it is targeting both cannabis and alcohol. The technology looks at a few hundred parameters on face and voice to identify if a person is impaired or not. The technology is very adaptable and has the potential to be rolled out anywhere on a massive scale. Dr. Kushwah also said that Cultivar is going to launch its impairment detection technology and is expecting to be revenue positive with its technology this year. He added that the company already has two agreements in place with multi-billion dollar companies like Tech Mahindra and Hindalco.

To access the complete interview, click here

Disclaimer: Cultivar Holdings Inc. is an advertorial member of InvestorIntel Corp.